Coronary Artery Disease Potentiates Response to Dofetilide for Rhythm Control of Atrial Fibrillation

Manocha, Pankaj; Bavikati, Venkata V.; Langberg, Jonathan J.; Lloyd, Michael S.

doi:10.1111/j.1540-8159.2011.03245.x

Cited by 8 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The success rate of dofetilide therapy in patients with coronary artery disease was 41.1%, compared to the 23.5% in those without coronary artery disease. 21…”

Section: Predictors Of Dofetilide Efficacymentioning

confidence: 99%

A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

Wolbrette

Hussain

Maraj

et al. 2018

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.

show abstract

“…The success rate of dofetilide therapy in patients with coronary artery disease was 41.1%, compared to the 23.5% in those without coronary artery disease. 21…”

Section: Predictors Of Dofetilide Efficacymentioning

confidence: 99%

A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

Wolbrette

Hussain

Maraj

et al. 2018

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Besides amiodarone, another class III antiarrhythmic, dofetilide, may be used in patients with AF and heart failure or coronary artery disease. The effectiveness of dofetilide was established for AF rhythm control in patients with a history of coronary artery disease in a cohort of 287 patients [ 121 ].…”

Section: The Vicious Circle Between Af and Ccsmentioning

confidence: 99%

Atrial Fibrillation and Chronic Coronary Ischemia: A Challenging Vicious Circle

Oancea,

Jigoranu,

Morariu

et al. 2023

Life

View full text Add to dashboard Cite

Atrial fibrillation, the most frequent arrhythmia in clinical practice and chronic coronary syndrome, is one of the forms of coronary ischemia to have a strong dual relationship. Atrial fibrillation may accelerate atherosclerosis and may increase oxygen consumption in the myocardium, creating a mismatch between supply and demand, thus promoting the development or worsening of coronary ischemia. Chronic coronary syndrome alters the structure and function of gap junction proteins, affecting the conduction of action potential and leading to ischemic necrosis of cardiomyocytes and their replacement with fibrous tissue, in this way sustaining the focal ectopic activity in atrial myocardium. They have many risk factors in common, such as hypertension, obesity, type 2 diabetes mellitus, and dyslipidemia. It is vital for the prognosis of patients to break this vicious circle by controlling risk factors, drug therapies, of which antithrombotic therapy may sometimes be challenging in terms of prothrombotic and bleeding risk, and interventional therapies (revascularization and catheter ablation).

show abstract

“…The drug has demonstrated both safety and efficacy in patients with coronary artery disease [84], and left ventricular dysfunction [85][86][87], but it does carry a risk of QT prolongation and Torsades de Pointes (TdP) and thus requires in-hospital initiation for 6 doses on continuous telemetry with QT monitoring on 12-lead ECGs after each dose. Initial dosing should be based on CrCl and adjusted with changing renal function or QTc prolongation.…”

Section: Dofetilidementioning

confidence: 99%

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

En¹,

Sk²

2017

Cardiovasc Pharm Open Access

View full text Add to dashboard Cite

Introduction: Cardiac arrhythmias, including supraventricular and ventricular tachycardias, portend a higher risk of morbidity and mortality. These arrhythmias also are associated with increased healthcare resource utilization, decreased quality of life, and increased activity impairment. Pharmacologic conversion is a treatment option for conversion to sinus rhythm that has the advantage of avoiding sedation from DC cardioversion.

show abstract

Coronary Artery Disease Potentiates Response to Dofetilide for Rhythm Control of Atrial Fibrillation

Abstract: In this large cohort of patients with AF, underlying coronary disease was significantly associated with dofetilide success. This finding may have utility for clinical decisions regarding initiation of dofetilide.

Cited by 8 publications

References 17 publications

A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

Atrial Fibrillation and Chronic Coronary Ischemia: A Challenging Vicious Circle

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

Contact Info

Product

Resources

About